(Stroke. 2001;32:1998.)
© 2001 American Heart Association, Inc.
Original Contributions |
From the Department of Radiology, University of Montreal (D.R., J.R.), and Department of Neurosurgery, Laval University, Québec, Canada (G.M.).
Reprint requests to Daniel Roy, MD, Department of Radiology, Notre-Dame Hospital-University of Montreal Health Center, 1560 Sherbrooke Street E, Montreal, Québec, Canada H2L 4 M1. E-mail daniel.roy.chum{at}ssss.gouv.qc.ca
| Abstract |
|---|
|
|
|---|
Methods We conducted an observational study from August 1992 to June 1999 of 125 unruptured aneurysms treated with GDC in 116 patients: 91 women (78.4%) and 25 men (21.6%), aged 30 to 78 years (mean age, 50.6 years). Immediate and late clinical results were recorded for any neurological event or hemorrhage related to the treated unruptured aneurysm. Angiographic results are reported as immediate, early (2 to 12 months), intermediate (12 to 30 months), and late follow-up (>30 months).
Results Immediate angiographic results showed complete obliteration (class 1) in 59 (47.2%) or residual neck (class 2) in 53 aneurysms (42.4%), leaving 6 residual aneurysms (4.8%) and 7 failures (5.6%). Early follow-up angiograms, available in 100 treated aneurysms (84%), revealed class 1 in 52% and class 2 in 41%. Intermediate angiograms, available in 53 aneurysms (44.5%), showed class 1 in 47.2% and class 2 in 43.4%, while late results, available in 37 lesions (31.1%), had class 1 and 2 in 48.6% and 37.8%, respectively. Six patients suffered a permanent neurological deficit at last follow-up (5.2%), with a good outcome in 5 patients and fair outcome in 1 patient. There was no mortality. There was no aneurysmal rupture during a mean clinical follow-up of 32.1 months.
Conclusions Endovascular treatment with GDC for unruptured aneurysms is relatively safe. Its role in the prevention of aneurysmal rupture remains to be determined, preferably by a randomized study.
Key Words: aneurysm cerebral aneurysm embolization, therapeutic
| Introduction |
|---|
|
|
|---|
During the last decade, endovascular treatment has been increasingly used, especially for ruptured lesions associated with a higher surgical morbidity or in patients in poor medical condition for surgery.1724 It has also been considered a valuable alternative treatment for unruptured aneurysms.25 Since the morbidity related to treatment is important to know with precision in this context and because it might differ from the morbidity reported in the acute setting, our first goal was to better define the risks of endovascular treatment of intracranial aneurysms in patients treated electively. Angiographic and clinical results were also recorded in an effort to estimate the efficacy of this strategy in the prevention of aneurysmal rupture.
| Subjects and Methods |
|---|
|
|
|---|
Patients and Aneurysms
There were 116 patients: 91 women (78.4%) and 25 men (21.6%). Age varied from 30 to 78 years (mean age, 50.6 years). Fifty-eight patients (50%) had multiple lesions, for a total of 226 aneurysms. One hundred twenty-five unruptured aneurysms in 116 patients were treated with selective GDC embolization and form the basis of this analysis. Of the other 101 aneurysms, 31 ruptured aneurysms were treated either surgically (n=21), by GDC (n=9), or by endovascular parent vessel occlusion (n=1). Twenty-four unruptured aneurysms were treated by surgical clipping and 6 by endovascular parent vessel occlusion. Forty small aneurysms (all <5 mm) were observed. The locations of the 125 unruptured aneurysms treated with GDC are summarized in Table 1. Ophthalmic segment aneurysms were most frequent (40%), followed by basilar bifurcation aneurysms (14.4%). The lesions were incidental in 65.5% of patients (eg, headaches, unrelated ischemic event or hemorrhage, family history, associated arteriovenous malformation). Thirty patients (25.9%) presented with SAH related to the rupture of another aneurysm, and 9 (7.8%) presented with cranial nerve dysfunctions.
|
The distribution of treated aneurysms according to size is illustrated in Figure 1. Eighty-five (68%) were small (
10 mm), and 40 (32%) were large (11 to 24 mm). Necks were considered small26 (
4 mm) in 78 aneurysms (62.4%) and wide (>4 mm) in 47 aneurysms (37.6%).
|
Endovascular Treatment
The technique for endovascular GDC treatment has been described previously.17,18 All procedures were performed on a monoplane C-arm angiographic system without 3-dimensional reconstruction. The procedure was performed with systemic heparinization in all cases. In some instances, heparin was continued for 24 hours, and patients were given aspirin 325 mg daily for 3 months. Most patients were treated under general anesthesia.
Complications
Neurological procedure-related complications were divided into thromboembolic or hemorrhagic events. Nonneurological complications such as puncture site hematomas or cardiopulmonary complications were also recorded. Significant thromboembolic events were defined as complications leading to persistent symptoms or those treated by thrombolytic agents or prolonged anticoagulation. All clinical complications were recorded before discharge and 1 month after treatment. All patients had a CT scan 24 hours after the procedure to detect asymptomatic lesions. Complications were defined as temporary when the deficit resolved within 1 month or permanent when present after 1 month. Morbidity was defined as the number of patients who sustained a permanent deficit.
Outcome
Further clinical follow-up data were collected during hospitalization for follow-up angiography or by telephone interviews. Patients outcome was graded according to the Modified Rankin Scale.27
Angiographic Results
Angiographic findings were recorded immediately, at 6 months, and yearly thereafter. Multiple projections with selective contrast injections served to define any residual lesions. Anatomic results were evaluated in a very strict fashion and classified as illustrated in Figure 2. A class 1 result meant complete obliteration. A residual neck (class 2) was defined as the persistence of any portion of the original defect of the arterial wall as seen on any single projection but without opacification of the aneurysmal sac. Any opacification of the sac was classified as residual aneurysm (class 3) and considered a failure of treatment. Because of difficulties in comparing angiographic projections from one study to the other, recurrence was defined as a change of classification of the anatomic result. When the aneurysm was considered occluded (class 1 or 2) despite minimal residual flow within the aneurysmal sac artificially maintained by systemic heparinization, the first angiographic follow-up result served as the "immediate result." This definition was used to minimize the number of aneurysms showing "improved results" at follow-up. Patients treated by surgery or parent vessel occlusion after failure of endovascular treatment or after recurrence were excluded from the tables reporting long-term angiographic outcome.
|
Statistical Analysis
Proportions were compared with the
2 test for categorical variables. ANOVA and Students t tests were used to compare continuous variables. All tests were performed with the use of a 5% confidence level. The incidence of thromboembolic events and initial morphological results were studied against age, aneurysm size, neck size, and aneurysm site. Recurrences were studied according to initial results, aneurysm size, neck size, and aneurysm site.
| Results |
|---|
|
|
|---|
Complications
Complications are summarized in Table 2.
|
Nonneurological Complications
Two patients presented symptomatic hypotension from large femoral hematomas that responded to volume expansion and local compression and did not require blood transfusion or surgical repair.
Thromboembolic Complications
Thromboembolic incidents occurred in 9 patients (7.8%). Three patients had occlusive symptomatic clots that were treated by local injection of urokinase (Abbott Laboratories) with complete clinical recovery in <24 hours. One patient with fibromuscular dysplasia presented a carotid dissection by the guiding catheter, leading to transient carotid occlusion. She secondarily developed a small subcortical infarct in the left sylvian territory and was left with very mild dysphasia (Rankin score I) at 20 months. Another patient, treated for a small carotid-ophthalmic aneurysm, presented ipsilateral blindness 4 hours after embolization. The ophthalmic artery was catheterized and infused with 750 000 U of urokinase, but the occlusion recurred and the patient did not recover useful vision of her eye. A third patient treated for a wide neck ophthalmic aneurysm presented acute right hemiplegia and aphasia from late coil displacement with protrusion and clot emboli 24 hours after treatment. Local injection of urokinase resulted in complete recanalization of the artery. She suffered a small parietal infarct with a right parietal hand (Rankin score I) at 43-month follow-up. One patient treated for a right MCA aneurysm developed transient ischemic attacks 1 week after embolization. Despite systemic heparinization, he developed a right frontal infarct with persisting constructive apraxia at 9 months (Rankin score II). Another patient showed transient right hemiparesis and right hemianopia the day after embolization of a wide neck basilar bifurcation aneurysm. Angiogram showed a nonocclusive clot in the P1 segment of the left posterior cerebral artery. Being asymptomatic at the time of angiography, she was put on anticoagulation therapy without recurrence of symptoms.
A significant neurological complication also occurred during follow-up angiography in a patient with a proximal basilar fenestration aneurysm. Vertebrobasilar emboli resulted in cerebellar and occipital infarction with a fair outcome score (Rankin III).
Hemorrhagic Complications
There were 3 perioperative aneurysm perforations (2.4%). Two occurred during initial catheterization of small aneurysms (<5 mm): 1 anterior communicating and the other pericallosal. The third occurred during attempts to recatheterize a large ophthalmic aneurysm that had already been partially filled with coils. Two were due to perforation by the guidewire and 1 by the microcatheter. In all 3 patients, extravasation was minimal and subsided rapidly after protamine injection and further coil embolization. One patient was asymptomatic. Another patient had monoparesis of her left leg due to secondary vasospasm but was asymptomatic at 1 month and at the 72-month follow-up. The third patient had complications not clearly related to the perforation itself. The lesion, a small anterior communicating aneurysm, was occluded, and the hemorrhage was rapidly controlled. The patient woke up with dense hemiplegia and aphasia. Angiography repeated immediately did not show any arterial occlusion or vasospasm. No clots were retrospectively found on multiple angiographic runs performed during treatment. MRI later showed ischemic lesions in the left anterior, middle cerebral, and anterior choroidal artery territories. The patient recovered in the following months but still suffers a minor motor deficit as well as mild neuropsychological impairment (Rankin score II) 1 year later. There was no statistical relationship between age and complication rate (P=0.4237). There was no significant association between adverse events and either site (P=0.483) or size (P=0.2899) of aneurysm.
Thus, the overall morbidity lasting >1 month related to endovascular management, including follow-up angiograms of unruptured aneurysms, was 5.2%, with 5 patients presenting a good outcome (3 Rankin score I and 2 Rankin score II) and 1 presenting a fair outcome (Rankin III). The morbidity strictly related to treatment was 4.3%, without any poor outcome. There was no mortality related to treatment.
Morphological Results
The morphological data are summarized in Table 3. Each patient had an average of 1.49 follow-up angiograms. Initially, 59 aneurysms (47.2%) were completely obliterated (class 1), and 53 (42.4%) showed a residual neck (class 2). There were 6 residual aneurysms (4.8%) (class 3) and 7 failures (5.6%). All failures occurred in aneurysms harboring an unfavorable neck-to-dome ratio.28 Of the 6 patients showing residual aneurysms, 3 were observed, 1 was treated by parent vessel occlusion, and 1 was retreated with GDC, but his large basilar bifurcation aneurysm with a wide neck keeps recurring. The sixth patient is planned for retreatment by parent vessel occlusion. When we analyzed variables associated with immediate angiographic outcome, small size of the aneurysm and small neck were associated with a higher percentage of 100% obliteration (P=0.002 and P=0.001, respectively). There was no other significant prediction of outcome.
|
Early angiographic follow-up (2 to 12 months) was available for 100 of the 118 treated aneurysms (84.7%). The results showed class 1 (n=52) or class 2 (n=41) results in 93% (95% CI, 85.6 to 96.9) of treated lesions. Intermediate angiographic follow-up (12 to 30 months), available in 53 aneurysms (44.9%), showed class 1 (n=25) or class 2 (n=23) results in 90.6% (95% CI, 78.6 to 96.5). Late angiographic follow-up (>30 months), available for 37 aneurysms (31.4%), revealed class 1 (n=18) or class 2 (n=14) results in 86.5% (95% CI, 69.7 to 94.8).
Recurrences
Four of the 50 completely obliterated lesions (8%) that had at least 1 follow-up angiogram showed a small recurrent neck on early (3 aneurysms) or intermediate (1 aneurysm) studies. In 2 of these patients, the residuum remained stable on subsequent follow-up angiogram, so that all aneurysms were in class 1 or 2 during the entire follow-up period. Of the 50 aneurysms with residual necks that had at least 1 follow-up angiogram, 6 (12%) evolved to the residual aneurysm category on either early (n=3) or late (n=3) follow-up studies. Of these, 3 were retreated by GDC and 1 by parent vessel occlusion. One is planned for retreatment with GDC, and 1 is being observed because of the patients age (70 years) and neurological deficits. The evolution of angiographic results of aneurysms with initial complete obliteration differed significantly from aneurysms with initial residual neck (P=0.011). None of the lesions that were initially 100% obliterated recurred to a class 3, while 12% of aneurysms left with residual necks became recurrent aneurysms. There was a clear trend of a higher incidence of recurrence to a class 3 result for wide-necked aneurysms, although this did not reach statistical significance (P=0.093). With the use of ANOVA, a statistically significant link was found between the risk of recurrence to a class 3 morphological outcome and the size of the aneurysm (P=0.0356). The aneurysmal site was not related to the risk of recurrence (P=0.585)
Clinical Follow-Up
Five patients died from unrelated causes during follow-up: 2 from lung cancer, 2 from myocardial infarction, and 1 from an intracerebral hematoma secondary to the rupture of an associated brain arteriovenous malformation. There was no SAH during a follow-up period varying from 1 to 81 months (mean, 32.1 months).
| Discussion |
|---|
|
|
|---|
The first goal of our study was to evaluate the morbidity associated with endovascular treatment of unruptured aneurysms. It may differ from morbidity associated with coiling during the acute phase after SAH. Since the bias introduced by case selection is likely to influence the results, we will discuss the characteristics of our study population and the potential implications on outcome. Complications will be reviewed and compared with other studies to identify the potential benefits of the endovascular approach in unruptured aneurysms. If endovascular treatment is shown to be safe, this advantage may be obtained at the cost of insufficient efficacy. We will finally discuss the problem of residual necks and recurrences: are they frequent enough to undermine any preventive endovascular strategy?
Characteristics of Patients and Aneurysms
This series is by definition a selected one because patients were referred by neurosurgeons who did not believe that surgical or conservative treatment was the best options for these patients. We excluded giant aneurysms from the study because they represent a specific subgroup at high risk16 of hemorrhage, often requiring combined treatments. We also excluded lesions for which our primary intention was parent vessel occlusion since the recurrence issue does not apply to this group. The location of aneurysms differs from surgical series with a higher incidence of ophthalmic and basilar aneurysms and a comparatively low incidence of MCA and posterior communicating aneurysms. This selection bias reflects the reality that the former 2 locations are often considered surgically more difficult.19,20 This selection may also have an impact on treatment efficacy since carotid-ophthalmic aneurysms are often underrepresented in ruptured aneurysm series, an observation that suggests a lesser tendency to bleed. Conversely, basilar tip aneurysms, overrepresented in the present series, showed the highest rupture rate in the ISUIA report.16 The small number of MCA aneurysms is related to selection bias by the endovascular team. The anatomic characteristics of these lesions have led to more frequent complications when they are treated by coiling.22 They were consequently more frequently excluded. Patients with multiple aneurysms (50%) are also more frequent than in most surgical series.3234 Although the risk of hemorrhage is higher in patients with multiple aneurysms,14,33 the morbidity and mortality related to multiple craniotomies also increase.34 Many patients have been managed by a combination of open surgery, endovascular treatment of larger aneurysms, and observation of smaller additional lesions. These latter aneurysms were either very small or had an unfavorable morphology for endovascular treatment. Some of these patients are thus still theoretically at risk of bleeding from untreated aneurysms.
Complications Related to Endovascular Treatment
We found that procedure-related morbidity and mortality were decreased compared with a synchronous observational study performed in our institution on endovascular treatment of acutely ruptured aneurysms.21 Perioperative ruptures were less frequent (2.4% compared with 8%), which may be self-explanatory because of a less fragile wall. Thromboembolic events, however, remained a significant problem (7.8%). While these events may be managed by therapeutic thrombolysis,35 they account for the majority of permanent complications. We observed a morbidity of 4.3% (with good outcome in all patients) or 5.2% if we include the complication related to a follow-up angiogram (endovascular management morbidity), with no mortality in 116 patients. These figures compare favorably with the results of surgical series.510 Furthermore, if surgical results are stratified to take into account lesions in more difficult locations (54.4% of patients of this series), the morbidity significantly increases to 18.7%.36 We did not find a relationship between age and complication rate, as reported by the ISUIA for surgery, but numbers are much smaller in the present study. Another endovascular series25 reported results almost identical to the present one. In this context, in which procedure-related morbidity should be low, endovascular treatment of unruptured aneurysms is an attractive alternative. However, future multicentric studies should be performed to confirm that the safety levels reported here can be reproduced in nonselected patients.
Morphological Results
Endovascular treatment is, by nature, less frequently complete than surgical clipping of aneurysms. Furthermore, recurrences are more frequent. It has been shown that exclusion of the aneurysmal sac, with or without a residual neck (class 1 and 2), is sufficient to prevent rebleeding in 98% of cases treated in the acute phase of SAH.21 Conversely, the presence of a residual aneurysm is associated with frequent rebleeding.21 By extension, when the result of endovascular treatment of unruptured aneurysms was class 3 (residual aneurysm), we considered that the patient was not protected from rupture. These considerations form the basis of our angiographic classification of morphological results. Class 1 and 2 results are protective from rebleeding after SAH, but, because class 2 results remain incompletely treated, they may, as shown by our data, be at higher risk of recurrence, and protection from rupture may not be definitive.
Our definition of recurrence may not reveal all morphological changes over time. We believe that it does reflect changes pertinent to this study. Consequently, our goal was to assess how often patients had unsatisfactory angiographic results (class 3) immediately after treatment and how often class 1 and 2 results had an evolution toward class 3 during follow-up. The true efficacy of endovascular treatment of unruptured aneurysms, which is prevention of rupture, cannot yet be determined, but it is important to assess the incidence of class 3 results immediately and over time, especially for the evaluation of this approach in the management of this population.
The failure rate (5.6%) was similar to that in the series of Murayama et al.25 Failure was always related to an unfavorable neck-to-dome ratio.28 Most of these aneurysms were treated before the advent of newer techniques such as balloon-assisted remodeling, 3-dimensional GDC, TriSpan neck bridge device, or stents. These new techniques may lower the failure rate. We report 47.2% of complete obliteration (class 1) and 42.4% of small residual necks (class 2) as initial results compared with 63.3% and 27.5%, respectively, in the series of Murayama et al.25 This discrepancy may be explained by differences in the criteria used for reporting anatomic results, which, unfortunately, are subjective and difficult to standardize.
All aneurysms showing immediate complete occlusion remained in the acceptable result category on late angiographic follow-up, but 4 (7.8%) went from class 1 to class 2 category. Most aneurysms (88%) with class 2 had stable results at follow-up, but 12% recurred to an unacceptable anatomic outcome (class 3). This evolution of angiographic results differs from the previous study.25 No recurrence was reported in the series of Murayama et al25 when complete obliteration was obtained immediately compared with a recurrence rate of 32% when residual necks were initially present. Their angiographic follow-up was, however, shorter, and the number of angiograms per patient was not indicated. As we and others37 have shown, recurrences may be revealed only on the second or third follow-up angiogram.
Overall, recurrences were documented during the entire follow-up period in a total of 10 of 100 aneurysms (10%) with initially class 1 or 2 result that had at least 1 follow-up angiogram. The recurrence rate to an unacceptable result (class 3) was 6.0%. These recurrences led to another form of treatment, whether by recoiling (n=3) or parent vessel occlusion (n=1) in 4 patients, with another patient being planned for recoiling. At the end of angiographic follow-up, class 1 or 2 results were still observed in 91.5% of actually treated aneurysms and 86.4% of the total number of lesions in which treatment was attempted (including failures). According to a quality-adjusted life-years study, for surgery to be as cost-effective as endovascular treatment, the reduction of the rupture rate obtained by coiling would have to be as low as
25%,31 which, owing to our morphological results, appears improbable. Thus, we believe that the incidence of class 3 results immediately and with time is not sufficient to discredit the endovascular approach as a preventive treatment against rupture.
Angiographic surveillance remains important. It is too soon to determine when follow-up imaging in a particular patient is no longer necessary because we have shown that recurrences may appear only on late follow-up. From our data, it is probably safe to propose follow-up angiography 1 year after treatment in case of complete obliteration and, if the result appears stable, to postpone further follow-up to 3 years later. When a residual neck is left after treatment, a 6-month follow-up is probably safer to pick up early recurrences. Until now, noninvasive imaging modalities, such as MR angiograpy,38 still have limitations due to artifacts produced by the platinum, but we expect significant improvement in the near future. This issue is important because a policy of multiple angiographic studies carries its own risk. Follow-up studies and the possibility of a second treatment may add to the psychological burden of management in terms of quality of life. This is difficult to quantify. We think that with the acquisition of more data over time, we will be able to have a better understanding of the evolution and propose a much lighter protocol for the patients.
Prevention of Aneurysmal Rupture
The number of patients (n=116) and the mean follow-up period (32.1 months) are insufficient to draw conclusions regarding long-term efficacy. We did not calculate the estimated number of hemorrhages that we should have encountered spontaneously during the same period without treatment because this number is highly dependent on aneurysm size, site, history of previous hemorrhage, and, above all, on a controversial natural history.510,29,30,36,39,40 However, it is reassuring that no bleeding episodes occurred and that 91.5% of treated lesions still had morphological results believed to protect from rupture at 30 months. There is only 1 reported case of late rupture of an apparently completely occluded unruptured aneurysm.41,42 In the series of Murayama et al25 of 115 patients, there was 1 late rupture 3 years after an incomplete treatment.
Should Unruptured Aneurysms Be Treated?
Since the bleeding risk of unruptured aneurysms is low, one can question whether any treatment should be proposed for small lesions. Since modern imaging reveals more and more unruptured intracranial aneurysms, it is of utmost importance to identify the best management of these patients. A cost-utility analysis,31 using different theoretical models of patients with unruptured aneurysms, showed no cost-effectiveness of either surgery or endovascular treatment for the basic model, which was a 50-year-old woman with an unruptured aneurysm of <10 mm in diameter without a previous history of hemorrhage. In this basic scenario, the annual bleeding rate was fixed at 0.05%. In all other models, treatment was cost-effective and more effective in terms of quality of life, with endovascular treatment being superior to surgery in all scenarios, even though the protection offered by endovascular treatment was fixed at 90% compared with 100% with surgical clipping.30
Even if this study is a series of consecutive patients without controls, it confirms the low morbidity of endovascular treatment and adds to the bulk of evidence that this approach may become more effective in terms of quality of life than surgery for unruptured aneurysms.23,25,31,37
Controversy will persist until a randomized study comparing conservative and active management of unruptured aneurysms is performed. Collecting prospective data in a randomized fashion is the only way to obtain true scientific evidence. We have studied various hypotheses and estimated population sizes; if safety and morphological results of the present study can be reproduced on a larger scale, such a randomized study comparing endovascular treatment and conservative management of unruptured aneurysms is feasible.
Conclusions
Endovascular treatment of unruptured aneurysms could be attempted safely in 95.7% of patients and without major neurological deficit in 100% of patients. Morphological results showed obliteration of the aneurysmal sac (with or without a residual neck) in 89.6% of lesions; recurrent opacification of the aneurysmal sac was observed in 6% of aneurysms. A longer follow-up period is necessary to determine efficacy, but there was no aneurysmal rupture during a mean period of 32.1 months. Because endovascular treatment is relatively safe and the natural history of unruptured aneurysms remains unknown, we propose to compare conservative and endovascular management of these patients in a randomized study.
| Acknowledgments |
|---|
Received September 25, 2000; revision received March 2, 2001; accepted June 6, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Standhardt, H. Boecher-Schwarz, A. Gruber, T. Benesch, E. Knosp, and G. Bavinzski Endovascular Treatment of Unruptured Intracranial Aneurysms With Guglielmi Detachable Coils: Short- and Long-Term Results of a Single-Centre Series Stroke, March 1, 2008; 39(3): 899 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gallas, J. Drouineau, J. Gabrillargues, A. Pasco, C. Cognard, L. Pierot, and D. Herbreteau Feasibility, Procedural Morbidity and Mortality, and Long-Term Follow-Up of Endovascular Treatment of 321 Unruptured Aneurysms AJNR Am. J. Neuroradiol., January 1, 2008; 29(1): 63 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.J. Rivet, C.J. Moran, A. Mazumdar, T.K. Pilgram, C.P. Derdeyn, and D.T. Cross Single-Institution Experience with Matrix Coils in the Treatment of Intracranial Aneurysms: Comparison with Same-Center Outcomes with the Use of Platinum Coils AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1736 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ries, S. Siemonsen, G. Thomalla, U. Grzyska, H. Zeumer, and J. Fiehler Long-Term Follow-Up of Cerebral Aneurysms after Endovascular Therapy Prediction and Outcome of Retreatment AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1755 - 1761. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bendszus, A. J. Bartsch, and L. Solymosi Endovascular Occlusion of Aneurysms Using a New Bioactive Coil: A Matched Pair Analysis With Bare Platinum Coils Stroke, October 1, 2007; 38(10): 2855 - 2857. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.S. Quadros, S. Gallas, R. Noudel, P. Rousseaux, and L. Pierot Endovascular Treatment of Middle Cerebral Artery Aneurysms as First Option: A Single Center Experience of 92 Aneurysms AJNR Am. J. Neuroradiol., September 1, 2007; 28(8): 1567 - 1572. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bendszus and L. Solymosi Cerecyte Coils in the Treatment of Intracranial Aneurysms: A Preliminary Clinical Study AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2053 - 2057. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Berenstein, J.K. Song, Y. Niimi, K. Namba, N.S. Heran, J.L. Brisman, M.C. Nahoum, M. Madrid, D.J. Langer, and M.J. Kupersmith Treatment of Cerebral Aneurysms with Hydrogel-Coated Platinum Coils (HydroCoil): Early Single-Center Experience. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1834 - 1840. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Katsaridis, C. Papagiannaki, and C. Violaris Guglielmi Detachable Coils versus Matrix Coils: A Comparison of the Immediate Posttreatment Results of the Embolization of 364 Cerebral Aneurysms in 307 Patients: A Single-Center, Single-Surgeon Experience. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1841 - 1848. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ries, J.-H. Buhk, T. Kucinski, E. Goebell, U. Grzyska, H. Zeumer, and J. Fiehler Intravenous Administration of Acetylsalicylic Acid During Endovascular Treatment of Cerebral Aneurysms Reduces the Rate of Thromboembolic Events Stroke, July 1, 2006; 37(7): 1816 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Gaba, S. A. Ansari, S. S. Roy, F. A. Marden, M. A.G. Viana, and T. W. Malisch Embolization of Intracranial Aneurysms With Hydrogel-Coated Coils Versus Inert Platinum Coils: Effects on Packing Density, Coil Length and Quantity, Procedure Performance, Cost, Length of Hospital Stay, and Durability of Therapy Stroke, June 1, 2006; 37(6): 1443 - 1450. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Pouratian, R J Oskouian Jr, M E Jensen, N F Kassell, and A S Dumont Endovascular management of unruptured intracranial aneurysms J. Neurol. Neurosurg. Psychiatry, May 1, 2006; 77(5): 572 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Niimi, J. Song, M. Madrid, and A. Berenstein Endosaccular Treatment of Intracranial Aneurysms Using Matrix Coils: Early Experience and Midterm Follow-Up Stroke, April 1, 2006; 37(4): 1028 - 1032. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Gauvrit, X. Leclerc, S. Caron, C. A. Taschner, J.-P. Lejeune, and J.-P. Pruvo Intracranial Aneurysms Treated With Guglielmi Detachable Coils: Imaging Follow-Up With Contrast-Enhanced MR Angiography Stroke, April 1, 2006; 37(4): 1033 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Raymond, F. Guilbert, A. Weill, and D. Roy Unruptured intracranial aneurysms: a call for a randomized clinical trial. AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 242 - 243. [Full Text] [PDF] |
||||
![]() |
I. Szikora, P. Seifert, Z. Hanzely, Z. Kulcsar, Z. Berentei, M. Marosfoi, S. Czirjak, J. Vajda, and I. Nyary Histopathologic evaluation of aneurysms treated with guglielmi detachable coils or matrix detachable microcoils. AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 283 - 288. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iijima, M. Piotin, C. Mounayer, L. Spelle, A. Weill, and J. Moret Endovascular Treatment with Coils of 149 Middle Cere |